RECURSION PHARMACEUTICALS, INC. (RXRX)
Nasdaq · Biological Products, (No Diagnostic Substances) · Inc. DE
What they're doing
Not enough recent activity to summarise.
Signals, last 12 months
- Material 8-K filingFiled 8-K disclosing material agreement
- Material 8-K filingFiled 8-K disclosing director or officer change
- Material 8-K filingFiled 8-K disclosing director or officer change
- Material 8-K filingFiled 8-K disclosing director or officer change
Insider transactions
| Date | Insider | Role | Code | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 2026-09-15 | Taylor Ben R | officer | F | 5,396 | 3.41 | $18,400 |
| 2026-09-08 | Khan Najat | director | S | 22,408 | 3.52 | $78,822 |
| 2026-09-01 | Borgeson Blake | director | S | 30,000 | 3.34 | $100,200 |
| 2026-08-17 | Khan Najat | director | F | 80,498 | 3.16 | $254,374 |
| 2026-08-17 | Hallett David | officer | F | 26,657 | 3.16 | $84,236 |
| 2026-08-17 | Taylor Ben R | officer | F | 25,018 | 3.16 | $79,057 |
| 2026-08-04 | Borgeson Blake | director | S | 30,000 | 3.25 | $97,500 |
| 2026-07-07 | Borgeson Blake | director | S | 40,000 | 3.96 | $158,500 |
| 2026-07-01 | Dar Zavain | director | A | 5,109 | 0 | $0 |
| 2026-07-01 | Li Dean Y | director | A | 3,747 | 0 | $0 |
| 2026-06-18 | Bumpus Namandje | director | S | 3,963 | 3.18 | $12,602 |
| 2026-06-18 | Bumpus Namandje | director | S | 3,963 | 3.18 | $12,602 |
| 2026-06-17 | Borgeson Blake | director | A | 88,424 | 0 | $0 |
| 2026-06-17 | HERSHBERG ROBERT | director | A | 88,424 | 0 | $0 |
| 2026-06-17 | Michor Franziska | director | A | 88,424 | 0 | $0 |
| 2026-06-17 | Sun Elaine D | director | A | 88,424 | 0 | $0 |
| 2026-06-17 | Dar Zavain | director | A | 88,424 | 0 | $0 |
| 2026-06-17 | Li Dean Y | director | A | 88,424 | 0 | $0 |
| 2026-06-17 | Bumpus Namandje | director | A | 88,424 | 0 | $0 |
| 2026-06-17 | Borgeson Blake | director | A | 88,424 | 0 | $0 |
| 2026-06-17 | HERSHBERG ROBERT | director | A | 88,424 | 0 | $0 |
| 2026-06-17 | Michor Franziska | director | A | 88,424 | 0 | $0 |
| 2026-06-17 | Sun Elaine D | director | A | 88,424 | 0 | $0 |
| 2026-06-17 | Dar Zavain | director | A | 88,424 | 0 | $0 |
| 2026-06-17 | Li Dean Y | director | A | 88,424 | 0 | $0 |
| 2026-06-17 | Bumpus Namandje | director | A | 88,424 | 0 | $0 |
| 2026-06-15 | Taylor Ben R | officer | F | 5,396 | 3.15 | $16,997 |
| 2026-06-15 | Taylor Ben R | officer | F | 5,396 | 3.15 | $16,997 |
| 2026-06-05 | Gibson Christopher | director | S | 40,000 | 3.62 | $144,800 |
| 2026-06-05 | Gibson Christopher | director | C | 40,000 | 0 | $0 |
| 2026-06-05 | Khan Najat | director | S | 23,588 | 3.58 | $84,445 |
| 2026-06-05 | Gibson Christopher | director | C | 40,000 | 0 | $0 |
| 2026-06-05 | Gibson Christopher | director | S | 40,000 | 3.62 | $144,800 |
| 2026-06-05 | Khan Najat | director | S | 23,588 | 3.58 | $84,459 |
| 2026-06-03 | Bumpus Namandje | director | S | 4,386 | 3.54 | $15,526 |
| 2026-06-03 | Bumpus Namandje | director | S | 4,386 | 3.54 | $15,526 |
| 2026-06-02 | Borgeson Blake | director | S | 30,000 | 3.68 | $110,400 |
| 2026-06-02 | Borgeson Blake | director | S | 30,000 | 3.68 | $110,400 |
| 2026-05-22 | Gibson Christopher | director | C | 40,000 | 0 | $0 |
| 2026-05-22 | Gibson Christopher | director | S | 40,000 | 3.08 | $123,200 |
| 2026-05-22 | Gibson Christopher | director | C | 40,000 | 0 | $0 |
| 2026-05-22 | Gibson Christopher | director | S | 40,000 | 3.08 | $123,200 |
| 2026-05-15 | Hallett David | officer | F | 26,657 | 3.04 | $81,037 |
| 2026-05-15 | Khan Najat | director | F | 62,701 | 3.04 | $190,611 |
| 2026-05-15 | Taylor Ben R | officer | F | 25,018 | 3.04 | $76,055 |
| 2026-05-15 | Gibson Christopher | director | F | 22,821 | 3.04 | $69,376 |
| 2026-05-15 | Hallett David | officer | F | 26,657 | 3.04 | $81,037 |
| 2026-05-15 | Khan Najat | director | F | 62,701 | 3.04 | $190,611 |
| 2026-05-15 | Taylor Ben R | officer | F | 25,018 | 3.04 | $76,055 |
| 2026-05-15 | Gibson Christopher | director | F | 22,821 | 3.04 | $69,376 |
Federal contracts
No federal contract actions on record for this recipient mapping.
Lobbying
No federal lobbying filings on record for this client mapping.
Public attention
No Wikipedia pageview data linked to this company.